Yifang Bio Stock Plunges 30%: Is the AI Drug Discovery Sector Losing Steam?
In the spring of 2026, Yifang Bio — once hailed as the 'Disneyland of Pharma' — saw its stock price plunge over 30%, tri…
🏷️ Biopharma
8 articles about 'Biopharma'
Mabwell Bio Scores $600M Google-Backed Deal, Successfully Completes Hong Kong IPO
After securing a $600 million partnership with a Google-affiliated company, Mabwell Bio successfully listed on the Hong …
Gilead Breaks 11-Year Key Level as AI Quantitative Analysis Projects 35% Upside
Gilead Sciences has completed its first key technical breakout in 11 years. AI-driven quantitative analysis models indic…
Chengda Biotech Invests 1 Billion Yuan to Establish AI Pharmaceutical Tech Company in Shanghai
Liaoning Chengda Biotech has established a wholly-owned subsidiary, Shanghai Chengda Zhiyuan Pharmaceutical Technology C…
Chinese Brokerages Lead Hong Kong IPO Sponsorship Market
Hong Kong's IPO market staged a strong comeback in 2025, with total fundraising approaching HK$290 billion to reclaim th…
RemeGen Q1 Net Profit Reaches 328 Million Yuan, Swinging From Loss to Profit
RemeGen released its Q1 2026 earnings report, posting revenue of 656 million yuan, a year-over-year increase of 24.76%, …
Xinmaide Closes Nearly 300 Million Yuan Series B Funding Round
Chinese drug delivery company Xinmaide has announced the completion of a nearly 300 million yuan Series B funding round …
Ligand Pharmaceuticals to Acquire XOMA Royalty Company for $740 Million
Ligand Pharmaceuticals announced it will acquire biotech royalty investment firm XOMA Royalty Company for approximately …
1